Drug Trial Radar · NCT01915498
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
345
Actual
Start
Aug 27, 2013
Primary completion
Jul 25, 2019
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Agios Pharmaceuticals, Inc.
- First posted
- Aug 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are: * To assess the safety and tolerability of treatment with enasidenib administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle in participants with advanced hematologic malignancies. * To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of enasidenib in participants with advanced hematologic malignancies. The primary objective of Phase 2 is: • To assess the efficacy of enasidenib as treatment for participants with relapsed or refractory (R/R) acute myelogenous leukemia (AML) with an IDH2 mutation.
Conditions
- Hematologic Neoplasms
Interventions
EnasidenibDrug
Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: From time of first dose up to the end of Cycle 1; 28 days
- Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff date of 01 September 2017; median treatment duration in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).
- Phase 1 Dose Expansion: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the first dose of investigational product (IP) up to 28 days after the last dose of IP up to the data cutoff date of 01 September 2017; median treatment duration in Part 1 Expansion was 5.2 months (range 0.5 to 32.8 months).
- Phase 2 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)Time frame: Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).
- Phase 2 Dose Expansion: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff of date of 01 September 2017; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).
- Safety Follow-up: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the primary analysis cut-off date of 01 September 2017 to the final analysis cut-off date of 29 July 2019, a maximum of 23 months.
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
City Of Hope
Duarte, California
Stanford Cancer Center
Stanford, California
University Of Colorado Cancer Center
Aurora, Colorado
University of Miami Sylvester Cancer Center
Miami, Florida
Florida Cancer Specialists
Sarasota, Florida
Moffitt Cancer Center
Tampa, Florida
Northwestern University
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber/Mass General Brigham Cancer Care, Inc
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
Cornell University Weill Medical College
New York, New York
Memorial Sloan-Kettering Cancer Center - NYC
New York, New York
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Gahanna, Ohio
Oregon Health and Science University OHSU
Portland, Oregon
Sarah Cannon Research Institute Drug Development Unit
Nashville, Tennessee
Ut Southwestern Medical Center At Dallas
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Local Institution - 202
Bordeaux, France
Local Institution - 204
Paris, France
Local Institution - 203
Pessac, France
Local Institution - 205
Toulouse, France
Local Institution - 201
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.